-
Neurocrine Biosciences Exceeds Expectations With Ingrezza Launch
Thursday, November 2, 2017 - 1:48pm | 661Read More...The performance of the tardive dyskinesia drug Ingrezza had sell-side analysts gushing over Neurocrine Biosciences, Inc. (NASDAQ: NBIX)'s third-quarter results. Given the buoyancy surrounding Ingrezza, analysts scrambled to designate Neurocrine as their top mid-cap pick. Ingrezza...
-
Attention Biotech Investors, Here's Your PDUFA Primer For October
Thursday, September 28, 2017 - 10:51am | 1961Read More...The biotech space can be an investor's delight, fetching staggering returns, while at the same time taking them through the throes of despair if bets go wrong — all courtesy of make-or-break events. In September, the iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB) has lost 0.44...
-
Neurocrine's Phase 2 Disappointment: Why The Company's Down, But Not Out
Wednesday, May 24, 2017 - 3:34pm | 292Read More...Neurocrine Biosciences, Inc. (NASDAQ: NBIX) shares fell sharply Wednesday following a disappointing phase 2 study of Ingrezza (valbenazine), a pediatric Tourette's syndrome drug. The company announced after Tuesday's close that Ingrezza didn't show a statistically significant difference on...
-
Neurocrine Outperforms Even Bullish Estimates Of Ingrezza Approval Upside
Wednesday, April 12, 2017 - 12:57pm | 404Read More...Shares of Neurocrine Biosciences, Inc. (NASDAQ: NBIX) soared by more than 20 percent Wednesday after the U.S. Food and Drug Administration granted approval for the company's Ingrezza therapy. Ingrezza is used by adults with tardive dyskinesia (TD) and has become the first treatment option...
-
Jefferies Maintains Buy on Neurocrine Biosciences
Friday, June 24, 2011 - 7:21am | 112Read More...Jefferies is out with its report today on Neurocrine Biosciences (NASDAQ: NBIX), maintaining Buy. In a note to clients, Jefferies writes, "NBIX announced it had a pre-IND meeting and is on track to file an IND in mid-July. Separately, the PTO granted the composition-of-matter patent covering its...
-
Piper Jaffray Maintains Overweight on Neurocrine Biosciences (NBIX)
Friday, March 25, 2011 - 9:52am | 169Read More...Piper Jaffray is out with its report today on Neurocrine Biosciences (NASDAQ: NBIX), maintaining Overweight. In a note to clients, Piper Jaffray writes, "We held meetings with management ahead of the end of Phase II meeting with the FDA for elagolix and VMAT2 Phase IIa data. We expect greater...
-
Neurocrine Biosciences Announces That VMAT2 Program Will Move Into Phase II Clinical Trials
Monday, October 18, 2010 - 8:11am | 335Read More...Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it has successfully completed a second Phase I clinical trial of its proprietary Vesicular Mono-Amine Transporter 2 compound, NBI-98854. The positive results of this Phase I study of repeated dosing in healthy volunteers allows the...
